Prestige Consumer Healthcare Inc. (PBH) — ESG & Values Scores

Environment story

PBH discloses minimal quantified environmental data. No Scope 1, 2, or 3 emissions are reported in the 10-K filing. No net-zero target year or decarbonization infrastructure investments are disclosed. The company acknowledges sustainability pressures from customers and regulators, including emerging Extended Producer Responsibility (EPR) regimes affecting packaging lifecycle management, but provides no specific mitigation commitments or baseline metrics. The company notes heightened regulatory activity on sterile eye care manufacturing as a constraint but does not articulate direct emissions reduction strategies. Absence of verified carbon inventories and targets, combined with supply chain dependency on third-party manufacturers (60% of production from 18 long-term contract manufacturers) with undisclosed emissions profiles, prevents substantive ESG scoring. Capped at 55 per Checklist A: company publicizes sustainability compliance efforts but does not disclose Scope 3 supply-chain emissions, which likely represent >70% of footprint in a consumer products business with global manufacturing and logistics.

Criticisms on file

No disclosed emissions inventory or net-zero target despite regulatory and customer pressure
Source: PBH 10-K Item 1A Risk Factors; MD&A Item 7
Regulatory scrutiny on sterile eye care manufacturing cited as ongoing industry-wide constraint; company's own facility acquired to address supply issues but environmental compliance not quantified
Source: PBH 10-K Item 1A Risk Factors – Regulatory Risks
Talcum powder product liability exposure: acquired low-volume talc-based product later discontinued (2017) due to contamination allegations; small number of lawsuits filed; most dismissed voluntarily; no material losses to date but reputational risk
Source: PBH 10-K Item 1A Risk Factors – Product Liability

Disclosed initiatives

Extended Producer Responsibility (EPR) Compliance

Company acknowledges evolving EPR regimes in jurisdictions where it operates, requiring participation in producer responsibility organizations, data tracking systems, packaging design modifications, and supply chain changes.

Increased compliance costs and capital expenditures; operational burden; risk of revenue loss if consumers shift brands or customers refuse to buy non-compliant products.
Manufacturing Facility Acquisition – Sterile Eye Care

Acquired Pillar5 (Arnprior, Ontario, Canada) manufacturing facility in December 2025; committed to long-term plant enhancements and capital investments to improve production consistency and supply reliability.

Short-term production disruptions offset by long-term supply security and operational control; capital investment required but no direct emissions reduction metrics disclosed.
Customer Sustainability Questionnaires

Major customers have requested sustainability evaluations since 2020; company responds to questionnaires on sustainability efforts.

Compliance activity; no substantive decarbonization or environmental performance commitments quantified.

Social story

PBH does not disclose CEO-to-worker pay ratio, workforce diversity metrics, turnover rates, or union standing in the 10-K filing. No labor relations controversies, strikes, or NLRB complaints are mentioned. The company acknowledges third-party manufacturing dependency (95 manufacturers; 60% of gross sales from 18 long-term contract partners) and has extended short-term loans to suppliers experiencing cash flow shortages, including one supplier that discontinued operations and did not repay (~$10.3M write-off in fiscal 2026). No supply-chain human rights audit, forced labor policy, or conflict minerals disclosures are reported. The company notes compliance with OSHA oversight and NLB oversight of certain suppliers. Diversity in technical and executive leadership is not disclosed. Without verified pay equity, union relations, or supply-chain ethics data, social score reflects absence of negative indicators (no active union suppression documented, no recent strikes, no major labor litigation) but penalizes opacity and missing commitments.

Criticisms on file

Supplier financial instability: short-term loan to pharmaceutical manufacturer not repaid after discontinuation; company wrote off ~$10.3M in fiscal 2026
Source: PBH 10-K Item 1A Risk Factors – Manufacturer Dependency
No disclosed supply-chain human rights audit, conflict minerals policy, or modern slavery statement
Source: PBH 10-K; absence of policy disclosure in filings
High manufacturing concentration: one supplier accounted for ~21% of gross revenues in fiscal 2026 and 2025; 60% of gross sales from 18 manufacturers; no long-term contracts with 77 of 95 suppliers
Source: PBH 10-K Item 1A Risk Factors – Manufacturer Dependency
No diversity metrics disclosed for executive or technical leadership
Source: PBH 10-K; absence in proxy or ESG disclosures

Disclosed initiatives

Third-Party Manufacturer Financial Support

Company has provided prepayments and short-term loans to suppliers experiencing cash flow shortages to ensure continuous supply.

Supply chain stabilization; financial risk (e.g., $10.3M loan write-off in fiscal 2026 when supplier discontinued operations); no documented labor or human rights vetting.
OSHA and NLB Compliance

Company and suppliers subject to Occupational Safety and Health Administration oversight and National Labor Relations Board oversight for certain suppliers.

Regulatory compliance; no proactive labor relations or diversity initiatives disclosed.
Product Liability Insurance

Company maintains product liability insurance and requires suppliers and third-party manufacturers to maintain coverage.

Risk mitigation for consumer safety; no evidence of worker safety or supply-chain labor audits.

Governance story

PBH has a single-class share structure with no disclosed dual-class voting (no penalty applied). Board independence percentage is not disclosed; no specific board composition data or independence metrics are reported in the 10-K filing. Annual lobbying expenditures are not disclosed in the filing; party lean cannot be inferred from PAC/political contributions (none reported in 10-K). No active antitrust proceedings, consumer-safety regulatory actions, or financial-fraud proceedings are documented. The company does not appear to be suing shareholder groups to block climate proposals. However, governance opacity—absence of board independence data, lobbying disclosure, PAC contribution data, and board committee structures—prevents higher scoring. The company is subject to restrictive covenants in its revolving credit facility and senior note indentures, which limit strategic flexibility and capital allocation (dividends, repurchases, acquisitions, asset pledging). No evidence of shareholder activism or contested proposals is disclosed.

Criticisms on file

No disclosed board independence percentage, board committee composition, or director appointment processes in 10-K
Source: PBH 10-K; data typically disclosed in proxy statement (not provided)
No disclosed annual lobbying expenditures or PAC contributions; unable to assess political alignment or regulatory advocacy positions
Source: PBH 10-K; not disclosed in filing
High indebtedness (~$1.0B as of March 31, 2026; expected to increase to ~$2.2B pending brand acquisition in H1 FY2027) constrains financial flexibility and strategic optionality
Source: PBH 10-K Item 1A Risk Factors – Financing; MD&A
Cross-default provisions in revolving credit facility and senior note indentures; aggregate indebtedness of ~$1.0B immediately due if default triggered; insufficient liquidity to repay if accelerated
Source: PBH 10-K Item 1A Risk Factors – Financing
No key-man insurance on senior management or executive officers
Source: PBH 10-K Item 1A Risk Factors – Key Personnel

Disclosed initiatives

Cybersecurity Governance and Risk Management

Company has implemented a Cybersecurity Incident Response Plan with escalation matrix; material cybersecurity matters escalated to Audit Committee; conducts quarterly employee security training; regular security audits by outside firm using NIST standards; maintains cybersecurity insurance.

Proactive risk governance; mitigates operational and reputational cybersecurity risk; insurance may have coverage gaps.
AI Technology Governance Committee

Internal AI policy restricts employee use of AI technologies; requires prior approval from AI Technology Governance Committee to evaluate security, compliance, and operational risks.

Emerging governance practice; addresses intellectual property, cybersecurity, and privacy risks from AI adoption; may limit operational agility.
Data Privacy and Compliance Program

Company has implemented compliance programs with updated security policies to address privacy, data protection, and cybersecurity regulations (CCPA, GDPR, state privacy laws).

Regulatory risk mitigation; operational complexity and cost from multi-jurisdictional compliance (20 U.S. states with comprehensive privacy laws as of January 2026).
Restricted Covenant Compliance

Company subject to restrictive covenants in revolving credit facility and senior note indentures; maintains financial covenants and fixed charge ratios.

Limited strategic flexibility; risk of default acceleration if covenants breached; constrains M&A, capital allocation, and liquidity management.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Prestige Consumer Healthcare Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Prestige Consumer Healthcare Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)